The FDA has approved both drugmakers’ RSV shots for use in adults 60 and older. GSK’s lawsuit alleges Pfizer’s Abrysvo vaccine infringes four patients used in its shot Arexvy. The Britain-based drugmaker is demanding a jury trial and is seeking monetary damages, including lost profits and royalties related to the alleged infringement.
“Upon information and belief, Pfizer knowingly uses the inventions claimed in the GSK Patents without permission,” GSK said in court documents reviewed by Becker’s, adding that Pfizer started on work on its RSV vaccine program as early as 2013, at least seven years after GSK started work on its shot for the respiratory illness.
A Pfizer spokesperson told CNBC it is “confident in its intellectual property position and will strongly defend its right to bring its innovative” RSV shot to patients.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
